Medical Affairs Project Associate Specialist New Grad Trainee
Alnylam Pharmaceuticals
Medical Affairs Project Associate Specialist New Grad Trainee
Alnylam Pharmaceuticals
Develops RNAi-based therapies for genetic diseases
The Medical Affairs Project Associate Specialist (post-grad trainee) will join the International Medical TTR team and report to International Medical Strategy & Operations. The post-grad trainee will support the planning, governance and execution of the international Medical Affairs Strategy for ATTR-CM across Alnylam's international markets, working closely with regional and country Medical teams and cross-functional partners. The role contributes to medical operations and planning deliverables, evidence generation portfolio, scientific engagement and insight programs, field medical excellence initiatives and patient experience work and offers first-hand insight into how a regional Medical Affairs organization is run. The scope is intentionally flexible: the more capability, initiative and curiosity the post-grad trainee brings, the more the remit can expand, in line with results.
Key Responsibilities
Qualifications
What We Bring
About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.
Our culture: Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we’ve been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as one of Science Magazine’s Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK – among others.
At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients.
Before applying, please review Alnylam's Candidate Privacy Notice regarding how Alnylam handles Personal Data you provide with your application for employment.
#LI-CC1 #LI-Hybrid
Develops RNAi-based therapies for genetic diseases
Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics to silence disease-causing genes, aiming to treat rare genetic disorders. Its products work by using RNA molecules that block gene expression, reducing the impact of specific genetic diseases. The company differentiates itself by concentrating on RNAi-based drugs for rare diseases and by building a pipeline through large clinical programs and strategic partnerships, such as commercialization deals in the Gulf States and collaborations with investors. Revenue comes from approved drug sales, licensing agreements, strategic collaborations, and related services like genetic testing and counseling. The company’s goal is to advance and commercialize RNAi therapies to improve outcomes for patients with genetic disorders, expanding its portfolio through partnerships and investments.
Explore more opportunities at Alnylam Pharmaceuticals